COMBINATIONS Russian patent published in 2025 - IPC A61K31/519 A61K31/437 A61K31/496 A61P35/02 

FIELD: medicine; pharmaceutics.

SUBSTANCE: invention relates to the pharmaceutical industry and medicine, specifically to a method for treating a disease or condition, wherein said disease or condition is selected from the group, consisting of haematological malignant neoplasm and lung cancer, wherein said haematological malignant neoplasm is selected from the group consisting of acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), chronic lymphocytic leukaemia (CLL), chronic myeloid leukaemia (CML), multiple myeloma and blast plasmacytoid dendritic cell neoplasm. Method of treating a disease or condition, wherein said disease or condition is selected from the group consisting of haematological malignant neoplasm and lung cancer, wherein said haematological malignant neoplasm is selected from the group consisting of acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), chronic lymphocytic leukaemia (CLL), chronic myeloid leukaemia (CML), multiple myeloma and blast plasmacytoid dendritic cell neoplasm, wherein said method comprises administering a combination, the combination comprising an effective amount of compound (A) and an effective amount of compound (B) or a pharmaceutically acceptable salt thereof, wherein compound (A) has the following structure:

wherein R¹ is hydrogen;

is selected from the group consisting of substituted , substituted and substituted , where ring B is substituted with 1 or 2 substituents independently selected from the group consisting of hydroxy, unsubstituted methyl and unsubstituted ethyl; R² is ; m is 0 or 1; R³ is unsubstituted C₁-C₆ alkyl; X is selected from the group consisting of and ; Y is CH; and compound (B) is a Bcl-2 inhibitor or a pharmaceutically acceptable salt thereof; wherein the Bcl-2 inhibitor is selected from the group consisting of venetoclax (ABT-199) and navitoclax (ABT-263) or pharmaceutically acceptable salts of any of said.

EFFECT: method described above is more effective in treating said diseases or conditions as compared to the monotherapy.

16 cl, 4 dwg, 2 tbl